Abstract: The invention relates to chimera molecules for targeting and releasing therapeutic compounds in mammals, especially humans. The inventive molecules comprise essentially three functional segments or domains: a targeting segment that can preferentially bind to the surface of the targeted cells, a therapeutic segment comprising the biologically active compound, and a linker segment between the targeting segment and the therapeutic segment, the linker segment being cleavable onto the target site. The invention also relates to the preparation of said molecules, to synthesis intermediates or domains thereof, to pharmaceutical compositions containing the same, and to the use thereof, especially in the pharmaceutical field. The molecules and compositions according to the invention are especially adapted to the targeting of pathological cells engaged in an apoptotic phase, and to the treatment of pathologies or associated tissues, especially cancers and inflammation.

Abstract: The present invention relates to a compound having affinity for a negatively charged phospholipid as well as to a detection molecule, to a conjugate and to a pharmaceutical composition comprising said compound. Generally speaking, the compound of the present invention is useful for specific recognition of lipid vectors. It may be used in engineering and in the generation of compound for recognizing and sequestrating of negatively charged lipids, such as phosphatidyl-serine and phosphatidic acid. The chemical structure of the present invention may have the construction (I).